Anti-breast cancer activity of heteroaryl chalcone derivatives

Biomedicine and Pharmacotherapy

Volumn 66, Issue 3, 2012, Pages 213-220

  Solomon, V Raja ^a,b   Lee, Hoyun ^a,b,c  

^a Regional Hospital   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Anticancer agents; Antiproliferative activity; Breast cancer; Chalcone

Indexed keywords

1 (4 CHLOROPHENYL) 3 [5 (4 METHOXYPHENYL)FURAN 2 YL]PROP 2 EN 1 ONE; CHALCONE DERIVATIVE; CISPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862807285     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.013     Document Type: Article

References (26)

1. Keshtgar M., Davidson T., Pigott K., Falzon M., Jones A. Current status and advances in management of early breast cancer. Int J Surg 2010, 8:199-202.
2. Maughan K.L., Lutterbie M.A., Ham P.S. Treatment of breast cancer. Am Fam Physician 2010, 81:1339-1346.
3. Zhao H., Cai Y., Santi S., Lafrenie R., Lee H. Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis. Radiat Res 2005, 164:250-257.
4. Hu C., Solomon V.R., Ulibarri G., Lee H. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 2008, 16:7888-7893.
5. Zhang H., Solomon V.R., Hu C., Ulibarri G., Lee H. Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives. Biomed Pharmacother 2008, 62:65-69.
6. Solomon V.R., Hu C., Lee H. Design and synthesis of chloroquine analogs with anti-breast cancer property. Eur J Med Chem 2010, 45:3916-3923.
7. Solomon V.R., Hu C., Lee H. Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: a hybrid pharmacophore approach. Bioorg Med Chem 2010, 18:1563-1572.
8. Solomon V.R., Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009, 625:220-233.
9. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging targeted therapies for breast cancer. J Clin Oncol 2010, 28:3366-3379.
10. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
11. Anto R.J., Sukumaran K., Kuttan G., Rao M.N., Subbaraju V., Kuttan R. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett 1995, 97:33-37.
12. Hsu Y.L., Kuo P.L., Tzeng W.S., Lin C.C. Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem Toxicol 2006, 44:704-713.
13. Lawrence N.J., Patterson R.P., Ooi L.L., Cook D., Ducki S. Effects of alpha-substitutions on structure and biological activity of anticancer chalcones. Bioorg Med Chem Lett 2006, 16:5844-5848.
14. Dominguez J.N., Leon C., Rodrigues J., Gamboa de D.N., Gut J., Rosenthal P.J. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J Med Chem 2005, 48:3654-3658.
15. Nielsen S.F., Christensen S.B., Cruciani G., Kharazmi A., Liljefors T. Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 1998, 41:4819-4832.
16. Lee S.H., Seo G.S., Kim J.Y., Jin X.Y., Kim H.D., Sohn D.H. Heme oxygenase 1 mediates anti-inflammatory effects of 2',4',6'-tris(methoxymethoxy) chalcone. Eur J Pharmacol 2006, 532:178-186.
17. Cheenpracha S., Karalai C., Ponglimanont C., Subhadhirasakul S., Tewtrakul S. Anti-HIV-1 protease activity of compounds from Boesenbergia pandurata. Bioorg Med Chem 2006, 14:1710-1714.
18. Bandgar B.P., Gawande S.S., Bodade R.G., Gawande N.M., Khobragade C.N. Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents. Bioorg Med Chem 2009, 17:8168-8173.
19. Dimmock J.R., Elias D.W., Beazely M.A., Kandepu N.M. Bioactivities of chalcones. Curr Med Chem 1999, 6:1125-1149.
20. Hsu Y.L., Kuo P.L., Chiang L.C., Lin C.C. Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer a549 cells. Clin Exp Pharmacol Physiol 2004, 31:414-418.
21. Fu Y., Hsieh T.C., Guo J., Kunicki J., Lee M.Y., Darzynkiewicz Z., et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 2004, 322:263-270.
22. Zi X., Simoneau A.R. Flavokawain A. A novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res 2005, 65:3479-3486.
23. Tabata K., Motani K., Takayanagi N., Nishimura R., Asami S., Kimura Y., et al. Xanthoangelol, a major chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma and leukemia cells. Biol Pharm Bull 2005, 28:1404-1407.
24. Takahashi T., Takasuka N., Iigo M., Baba M., Nishino H., Tsuda H., et al. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci 2004, 95:448-453.
25. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112.
26. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.